Help me do the math

Quote

Anonymous

Guest
Ok guys. After the Aliskiren bomb dust clears, what's left for us to sell?
I believe that when the dust settles, we will still be promoting Aliskiren brands (less Valturna), but only as a "stand-alone" agent without the diabetes pt type, or ace/arb combo. It is still safe and effective on its own, right? So let's pretend that we still need someone to sell that as much as a niche as it is. (after ACE, after ARB..... then Aliskiren?)
Next is Exforge/Hct- I this will still be in the game for a while. Remember Lotrel? There were plenty of Gx ACES and CCB's on the market, including amlodipine, and Lotrel still delivered over 1B per year in the US prior to having it's patent challenged. I believe we will still be selling Exforge/Hct for a while.
Exelon Patch- with it's new dose, this should give us a longer term opportunity. Why not incentivize Comtan & Stalevo to bolster our portfolio? That would add 2 more products.
Reclast- 1 more year then done. Arcapta will be launched in 2012 as well.

I believe the right number will be 3. FLM's will consolidate significantly so each has 12 reps. (4 territories instead of 2, means a 50% cut at the FLM level since most have 2 territories)

What do you think of these assumptions, and how many per territory will we need?
 












Comtan and Stalevo go generic 2012. And trust me, after selling both for a long time, you don't want to have anything to do with either. Similar to what just happened with Aliskiren, the trial that would have expanded Stalevo use failed, and that is why it is just a sample drop now. Only a handful of docs use Stalevo and Comtan anyway. And the coverage is horrible, and it's expensive.
 






Everyone knows, including your docs that hypertension is a generics market. Nice try with exforge hct- that won't be enough to support more than a few reps. We knew diovan going generic was going to cost jobs, this makes the cuts deeper. Remember when we stopped lotrel, it was 'temporary' also.
 






Anonymous said:
Everyone knows, including your docs that hypertension is a generics market. Nice try with exforge hct- that won't be enough to support more than a few reps. We knew diovan going generic was going to cost jobs, this makes the cuts deeper. Remember when we stopped lotrel, it was 'temporary' also.
Click to expand...

Exforge HCT bwahahahahahaha

"Doctor why have your patients save 80% on generic valsartan hct & amlodipine
when they can pay triple for the NOVARTIS brand , you know NOVARTIS ,
the house of hypertension , King of RAAS suppression, promoter of aliskren
for diabetes . Have I shown you this honararium check ? It's a really nice check !
Do you know we offer upgraded lunch packages from Ruth Chris , Wolfgang Puck ,
Gordon Ramsey , Emeril Lagasse & Mario Batali ?
It's a really good lunch !! "
 






Anonymous said:
Ok guys. After the Aliskiren bomb dust clears, what's left for us to sell?
I believe that when the dust settles, we will still be promoting Aliskiren brands (less Valturna), but only as a "stand-alone" agent without the diabetes pt type, or ace/arb combo. It is still safe and effective on its own, right? So let's pretend that we still need someone to sell that as much as a niche as it is. (after ACE, after ARB..... then Aliskiren?)
Next is Exforge/Hct- I this will still be in the game for a while. Remember Lotrel? There were plenty of Gx ACES and CCB's on the market, including amlodipine, and Lotrel still delivered over 1B per year in the US prior to having it's patent challenged. I believe we will still be selling Exforge/Hct for a while.
Exelon Patch- with it's new dose, this should give us a longer term opportunity. Why not incentivize Comtan & Stalevo to bolster our portfolio? That would add 2 more products.
Reclast- 1 more year then done. Arcapta will be launched in 2012 as well.

I believe the right number will be 3. FLM's will consolidate significantly so each has 12 reps. (4 territories instead of 2, means a 50% cut at the FLM level since most have 2 territories)

What do you think of these assumptions, and how many per territory will we need?
Click to expand...

I think your assumptions will never come to be....Tekturna will be dead. DO you think after the reps go and tell the Drs this great news and the Drs have to switch most of not all their patients which will take alot of time for them, they would even think twice about RXing Tekturna again in the future. I highly doubt it but maybe.

2 reps per pod will be able to handle all the wonderful drugs we now have to sell for the next year. i
 






To the Moron that is the original poster let me break it down for you

1. Tekturna alone is as effective as a jelly bean. I launched the drug as well as its bastard step children and the only way it works is as a combo.

2. Exforge/HCT - here is a term to look up "HEALTH CARE REFORM" do you think managed care is going to pay for this once Diovan goes....Not a chance. There may be a few months of lead time but nothing long term

3. Exelon Patch may get a new dose and probably will. How much market share does patch have ? Right once again buying time not saving grace. Sold patch and let me tell you if they are not using the lower dose patch now there is no way they will use this.

4. Stalevo/Comtan is not a Novartis product we are contracted to sell it. With that said starting in April of 2015 Sun Pharma will be allowed to make a generic version of 25/100/200 and 37.5/150/200. In October of 2012 the can sell generic Comtan. Any questions?

5. Reclast will be here till March of 2013 but I am guessing based on your inital post you will not be

6. Arcapta is not being given to Gen Meds. How many COPD drugs have you sold? Do you have relationships with Pulmonologist ? You may get it but my guess is that it will be easier to have TOBI or Xolair call on key Primary Care docs in addition to their current plan

You forgot to mention Fanapt let me give you the scoop on that one. Fanapt is a Vanda product that was bought for 200 million. In its launch year it brought in a little over 30 million this year it will make somewhere around 45 million. Bottom line it is not profitable.

Last but not least Focalin XR. The lower doses go generic this year. We still have some life with the higher ones. The brand had been really successful at marketing directly to doctors in fact they have been hitting all time highs in terms of scripts. Once again buying time not saving grace

Bottom line will there be reps..... yes of course
Will it be a blood bath ......you bet

Hang on kids it is going to a bumpy ride!

xoxo
your friend on the inside
 












Dude, you need to throw some cold water on your face and wake up. The picture you just painted is a best, and I mean ABSOLUTE BEST case scenario. The reality will be much worse.
 






Anonymous said:
To the Moron that is the original poster let me break it down for you

1. Tekturna alone is as effective as a jelly bean. I launched the drug as well as its bastard step children and the only way it works is as a combo.

2. Exforge/HCT - here is a term to look up "HEALTH CARE REFORM" do you think managed care is going to pay for this once Diovan goes....Not a chance. There may be a few months of lead time but nothing long term

3. Exelon Patch may get a new dose and probably will. How much market share does patch have ? Right once again buying time not saving grace. Sold patch and let me tell you if they are not using the lower dose patch now there is no way they will use this.

4. Stalevo/Comtan is not a Novartis product we are contracted to sell it. With that said starting in April of 2015 Sun Pharma will be allowed to make a generic version of 25/100/200 and 37.5/150/200. In October of 2012 the can sell generic Comtan. Any questions?

5. Reclast will be here till March of 2013 but I am guessing based on your inital post you will not be

6. Arcapta is not being given to Gen Meds. How many COPD drugs have you sold? Do you have relationships with Pulmonologist ? You may get it but my guess is that it will be easier to have TOBI or Xolair call on key Primary Care docs in addition to their current plan

You forgot to mention Fanapt let me give you the scoop on that one. Fanapt is a Vanda product that was bought for 200 million. In its launch year it brought in a little over 30 million this year it will make somewhere around 45 million. Bottom line it is not profitable.

Last but not least Focalin XR. The lower doses go generic this year. We still have some life with the higher ones. The brand had been really successful at marketing directly to doctors in fact they have been hitting all time highs in terms of scripts. Once again buying time not saving grace

Bottom line will there be reps..... yes of course
Will it be a blood bath ......you bet

Hang on kids it is going to a bumpy ride!

xoxo
your friend on the inside
Click to expand...

You GROSSLY underestimate jelly beans
PS- we have no friends , inside or out .
 






Top Bottom
Back
Quote